Alphanate250 IU/vial

Alphanate is a plasma-derived Antihemophilic Factor/von Willebrand Factor (FVIII/VWF) Complex (Human) concentrate. It is FDA-approved and used under specialist supervision for:

• Hemophilia A (Factor VIII deficiency): Established, on-label use for the treatment and prevention (prophylaxis) of bleeding episodes, including perioperative (surgical) bleeding management.
• Von Willebrand Disease (VWD), Type 1 and Type 2: Guideline-supported use for perioperative and bleeding-episode management in patients for whom desmopressin (DDAVP) is known or suspected to be ineffective, or is contraindicated.
• Von Willebrand Disease, Type 3: Established use for the perioperative management of minor surgery.

Alphanate is not indicated as first-line therapy where desmopressin or non-factor therapies are effective, and is not intended for self-directed use outside a hemophilia/hematology treatment program.

Each vial of Alphanate contains lyophilized Antihemophilic Factor/von Willebrand Factor Complex (Human), a concentrate of Factor VIII (FVIII) and von Willebrand Factor (VWF) purified from pooled human plasma using a combination of heat treatment, solvent/detergent treatment, and immunoaffinity chromatography (which uses a mouse/murine monoclonal antibody). Alphanate is supplied with a diluent (Sterile Water for Injection) for reconstitution. Potency is labeled in International Units (IU) of Factor VIII activity and VWF:RCo (ristocetin cofactor) activity per vial.

Alphanate is a specialized, plasma-derived biologic medicine, not a conventional small-molecule drug. It replaces missing or deficient clotting Factor VIII and von Willebrand Factor in the blood, allowing normal clot formation in people with hemophilia A or von Willebrand disease. Alphanate is administered only by intravenous (IV) infusion, typically in a hospital, infusion center, or hemophilia treatment center, or by patients/caregivers trained in home infusion under specialist guidance.

Alphanate belongs to the therapeutic class of Antihemophilic Factor concentrates (plasma-derived Factor VIII/von Willebrand Factor complex), used in hematology for bleeding disorder replacement therapy.

Mechanism: Alphanate temporarily replaces the deficient clotting Factor VIII and/or von Willebrand Factor. Infused Factor VIII binds to endogenous von Willebrand Factor in the patient's circulation, stabilizing FVIII and correcting the intrinsic coagulation pathway defect in hemophilia A, which restores the ability to form a stable fibrin clot at sites of vascular injury.

In von Willebrand Disease, the von Willebrand Factor component of Alphanate restores platelet adhesion to the damaged vessel wall (via binding to platelet glycoprotein Ib and subendothelial collagen) and also stabilizes endogenous/infused Factor VIII, correcting both the primary hemostasis defect and any secondary FVIII deficiency.

Recovery and half-life vary by patient and are individualized using factor level (FVIII:C or VWF:RCo) monitoring; typical FVIII half-life is approximately 8-19 hours.

Alphanate is for intravenous infusion only, after reconstitution with the accompanying diluent. It should be administered at a controlled infusion rate as directed by the treating physician or the product instructions, using the administration set provided. Alphanate must not be mixed with other medicinal products or diluted beyond what is specified. Administration should occur in a setting where treatment of acute hypersensitivity/anaphylactic reactions is available.

No formal drug-interaction studies have been conducted with Alphanate. Because Alphanate contains both Factor VIII and von Willebrand Factor, clinically important considerations include:

• Concomitant use with other coagulation factor concentrates or bypassing agents should be coordinated by a hematologist to avoid over- or under-correction of clotting factor levels.
• In patients with pre-existing thrombotic risk factors, concurrent use of Alphanate (particularly at high or repeated doses) with other pro-thrombotic agents or antifibrinolytics may increase thromboembolic risk (see Precautions).

Inform the treating physician of all other medicines, including antifibrinolytics (e.g., tranexamic acid) used alongside Alphanate.

Most reported reactions to Alphanate are infrequent (affecting roughly 1% or fewer of infusions). Reported adverse effects include:

• Common: pruritus (itching), headache, back pain, paresthesia, facial or peripheral edema, chills, rash, and general pain at or beyond the infusion site.
• Less common but serious: hypersensitivity/allergic reactions up to anaphylaxis (rash, hives, chest tightness, wheezing, hypotension), thromboembolic events (especially with VWF-containing products at high/repeated doses), and development of inhibitory antibodies to Factor VIII.
• Rare: hemolysis (in patients with non-O blood groups receiving large or repeated doses), fever, and transmission of blood-borne infectious agents (see Precautions).

Report any new or worsening symptoms after Alphanate infusion to the treating physician immediately.

Alphanate has not been formally assigned an FDA pregnancy category and has not been evaluated in controlled studies in pregnant women. As a plasma-derived replacement product for a specific factor deficiency, Alphanate should be used in pregnancy only if clearly needed, such as for treatment or prevention of bleeding in a woman with hemophilia A or von Willebrand disease, and only under specialist supervision, with the potential benefit weighed against any potential risk. It is not known whether Alphanate is excreted in human milk; caution is advised, and a physician should be consulted before use of Alphanate during breastfeeding.

Hypersensitivity/Anaphylaxis: As with any plasma-derived protein product, allergic-type hypersensitivity reactions, including anaphylaxis, are possible with Alphanate. Patients should be informed of early signs (hives, generalized urticaria, chest tightness, wheezing, hypotension, anaphylaxis) and instructed to discontinue the infusion and seek immediate medical attention if these occur.

Infectious agent transmission: Because Alphanate is made from pooled human plasma, it may carry a risk of transmitting infectious agents, including viruses and, theoretically, the variant Creutzfeldt-Jakob disease (vCJD) agent, despite viral inactivation/screening steps used during manufacture. Discuss any concerns about this residual risk with the treating physician.

Thromboembolic events: Thrombosis has been reported, particularly with VWF-containing concentrates such as Alphanate, especially at high or repeated doses, in patients with cardiovascular risk factors, or during surgery. Clinical monitoring for early signs of thrombosis is recommended in at-risk patients receiving Alphanate.

Inhibitor development: Formation of neutralizing (inhibitory) antibodies to Factor VIII is a recognized complication of replacement therapy. If a patient does not achieve the expected clinical response or factor level after an adequate dose of Alphanate, inhibitor testing should be performed.

Alphanate must only be used under the direction of a physician experienced in the management of hemophilia A or von Willebrand disease; it is a specialist biologic product, not a routine outpatient medicine.

No specific syndrome of Alphanate overdose has been well characterized, but excessive dosing may theoretically increase the risk of thromboembolic complications, particularly with the von Willebrand Factor component. If an overdose of Alphanate is suspected, or if symptoms such as chest pain, shortness of breath, limb swelling, or unusual bleeding occur, seek immediate medical attention or contact emergency services/poison control. Do not attempt to manage a suspected overdose of Alphanate at home.

Store Alphanate at temperatures not exceeding 25°C (77°F). Do not freeze. Keep the vial in its original carton, protected from light, until the time of reconstitution. Keep out of reach of children. Once reconstituted, use Alphanate within 3 hours and do not refrigerate the reconstituted solution.

Renal/Hepatic impairment: No specific dose adjustment of Alphanate has been established for renal or hepatic impairment; use with the same individualized, factor-level-guided dosing approach, with additional clinical monitoring as needed.

Elderly: Limited data exist specifically in elderly patients; dosing of Alphanate should follow the same weight- and factor-level-based approach, with attention to any concurrent cardiovascular risk factors that could increase thromboembolic risk.

Pediatric use: see Pediatric Uses section.

Pregnancy/Lactation: see Pregnancy and Lactation section.

Duration of treatment with Alphanate depends entirely on the clinical indication: a single infusion or short course for a minor bleed, several days of repeated dosing for major bleeds or surgery (guided by serial factor level monitoring), or long-term intermittent/prophylactic use in patients with severe hemophilia A, as determined by the treating hematologist.

Alphanate is supplied as a lyophilized (freeze-dried) powder that must be reconstituted before use. Bring both the Alphanate vial and the accompanying diluent (Sterile Water for Injection) to room temperature. Reconstitute using the transfer device supplied with the kit, following the manufacturer's instructions exactly; gently swirl (do not shake) until the powder is fully dissolved. Inspect the reconstituted solution visually for particulate matter and discoloration before administration, and use within 3 hours of reconstitution.

Alphanate is classified as a plasma-derived coagulation factor concentrate (Antihemophilic Factor/von Willebrand Factor Complex, Human), within the broader biologic drug class of hemostatic/antihemorrhagic agents.

Alphanate works by directly supplying the coagulation proteins (Factor VIII and von Willebrand Factor) that are deficient or defective in hemophilia A and von Willebrand disease. Infused Factor VIII participates in the intrinsic coagulation cascade to generate thrombin and fibrin, forming a stable clot; infused von Willebrand Factor mediates platelet adhesion at sites of vessel injury and protects circulating Factor VIII from premature degradation, together restoring effective hemostasis.

Alphanate is approved for use in pediatric patients with hemophilia A of all ages for treatment and prevention of bleeding, and in pediatric patients with von Willebrand Disease (Types 1, 2, and 3) for perioperative management, using weight-based dosing (e.g., approximately 75 IU VWF:RCo/kg pre-operatively and 50-75 IU/kg for maintenance dosing in VWD, adjusted per factor level monitoring). Alphanate should be administered to children only under the supervision of a pediatric hematologist or hemophilia treatment center, with careful attention to venous access and infusion rate.